Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Mangoceuticals, Inc. ( (MGRX) ) has shared an announcement.
Mangoceuticals, Inc. entered into a Debt Conversion Agreement with Mill End Capital Ltd. on January 15, 2025, converting a $150,000 debt into 100,000 shares of restricted common stock. The agreement led to the repricing of warrants and the conversion price of Series B Preferred Stock to $1.50 per share. On the same date, the company completed the final sale of 250 shares of Series B Preferred Stock to an institutional investor for $250,000. Antonios Isaac was also appointed as a new member of the Board of Directors and as President of the company.
More about Mangoceuticals, Inc.
YTD Price Performance: 4.82%
Average Trading Volume: 95,863
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.49M
Learn more about MGRX stock on TipRanks’ Stock Analysis page.
